A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
- Registration Number
- NCT04089449
- Lead Sponsor
- Prelude Therapeutics
- Brief Summary
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.
- Detailed Description
This is a multicenter, open-label, dose-escalation, dose-expansion Phase 1 study of PRT811, a PRMT5 inhibitor, in subjects with advanced cancers without any approved or available treatment options including solid tumors, CNS lymphoma, and /or high-grade gliomas. The study will consist of 2 parts, a dose escalation part evaluating subjects with advanced solid tumors, CNS lymphoma, and/or high-grade glioma and a cohort expansion part which will evaluate the safety and efficacy of PRT811 in subjects with advanced solid tumors, and glioblastoma multiforme. For subjects, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. An end-of-study visit will be conducted within 30 days after the last dose of PRT811.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
- Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies
- Subjects must have recovered from the effects of any prior investigational system therapies
- For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias.
- For biomarker-selected solid tumors: must meet enrollment criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1
- Adequate organ function (bone marrow, hepatic, renal, cardiovascular)
- Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial
- Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year
- Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic substitutions
- Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption
- HIV positive; known active hepatitis B or C
- Known hypersensitivity to any of the components of PRT811
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description PRT811 PRT811 PRT811 will be administered orally
- Primary Outcome Measures
Name Time Method To describe dose limiting toxicities (DLT) of PRT811 Baseline through Day 21 Dose limiting toxicities will be evaluated through the first cycle
To determine the maximally tolerated dose (MTD) Baseline through approximately 2 years The MTD will be established for further investigation in participants with solid tumors and gliomas
To determine the recommended phase 2 dose (RP2D) and schedule of PRT811 Baseline through approximately 2 years The RP2D will be established for further investigation in participants with solid tumors and gliomas
- Secondary Outcome Measures
Name Time Method To describe the adverse event profile and tolerability of PRT811 Baseline through approximately 2 years Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy
To describe the pharmacokinetic profile of PRT811 Cycle 1 (each cycle is 21 days) on Days 1, 8 and 14. For subsequent cycles, Day 1 of each cycle through the end of study treatment, an average of 6 months PRT811 pharmacokinetics will be calculated including the maximum observed plasma concentration
To describe any anti-tumor activity of PRT811 Baseline through approximately 2 years Anti-tumor activity of PRT811 will be based on the measurement of objective responses
Trial Locations
- Locations (11)
The Ohio State University and Wexner Medical Center
🇺🇸Columbus, Ohio, United States
Northwestern Memorial Hospital
🇺🇸Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Sarah Cannon Research Institute at HealthONE
🇺🇸Denver, Colorado, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Florida Cancer Specialists
🇺🇸Lake Mary, Florida, United States
Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
Washington University School of Medicine - Siteman Cancer Center
🇺🇸Saint Louis, Missouri, United States
Christiana Care Health Services, Christiana Hospital
🇺🇸Newark, Delaware, United States
Georgia Cancer Center at Augusta University
🇺🇸Augusta, Georgia, United States
Yale- New Haven Hospital- Yale Cancer Center
🇺🇸New Haven, Connecticut, United States